Laurence Rulleau
Partner, CTI LSF
Dr. Terrisse-Rulleau brings 25 years of experience in investing in life sciences and building companies in the sector. Dr Laurence Terrisse Rulleau has been a partner with CTI Life Sciences fund since 2014 where she has played a key role in the fund’s investments including the creation of companies such as Find Therapeutics and Epitopea, as well as the sale of Amolyt Pharma to AstraZeneca. Prior to joining CTI LSF II, Laurence served as Vice-President Business Development at Univalor where she oversaw the licensing of 55 compounds to the industry and created 8 spin-off companies. She also previously served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. Dr. Rulleau was ranked Canada’s leading life sciences analyst by the Starmine survey and the first independent analyst by the Brendon Wood poll. Laurence is also very active in the life science Canadian community and is a director on the Board of Directors of Dalcor, Find Therapeutics, Epitopea and DTX Bio. Additionally, she is a member of Women Innovating Together in Healthcare (WITH), Women in BIO (WIB) and Reseau-ELLE. Dr. Rulleau holds a master’s degree in biology from the University of Quebec at Montreal (UQAM) and a Ph.D. from the University of Montreal in immunology executed at Montreal Clinical Research Institute.